Biointelect taking innovation from science to market


Biointelect’s offering of bringing ‘Science to Market’ is growing with the addition of new team members giving the company’s clients access to an expanded range of expertise.

Biointelect was established in 2011 by experienced and well-known life sciences executive Jenny Herz. Husband Karl subsequently joined the company. Both have extensive experience and are well known across the life sciences sector.

The company provides consulting services to companies and organisations developing and commercialising new biopharmaceutical and medical technologies by evaluating clinical, regulatory and economic evidence to support a highly targeted and effective market entry strategy.

Biointelect has grown rapidly and its clients include some of the most recognised brands in the life sciences sector and in medical research.

Biointelect has also expanded its service offering over time, now covering the value chain from development to commercialisation, including working with companies on market evaluation, identifying potential partners, contract negotiation, refining an investor pitch and establishing operations.

Recent case studies include a pipeline analysis for a company with a gene therapy, market entry plans for a respiratory product in developing countries, the review of a company’s unsuccessful approach to potential partners, securing university funding for a new pre-clinical drug candidate, a European market strategy for a US biotech, and advising a company on establishing an Australian presence.

With expansion comes the addition of new team members. The company recently announced the appointment of former senior industry executives Peter Miles and Paul Cohen, saying their addition has significantly added to Biointelect’s expertise in a wide range of therapeutic areas, diagnostics and medical devices.

Mr Miles has spent over three decades in the health care industry in senior commercial roles in Australia and across the region. He has overseen the launch of products across multiple therapeutic areas and brings a wide range of experience across prescription, over-the-counter and generic medicines, as well as medical devices.

Mr Cohen has more than two decades experience in the diagnostics, biotechnology, medical device and pharmaceutical industries. He has worked for large multinational companies and start-ups in functions spanning clinical research, regulatory affairs, pharmacovigilance, training, quality management and process re-engineering.

The company also announced a number of other appointments.

Dr Elizabeth Heller has joined Biointelect as a senior consultant. Dr Heller holds a BA in Biological Sciences and Chemistry magna cum laude from Cornell University, a Masters of Medical Sciences from Harvard Medical School and a PhD in Biochemistry and Molecular Pharmacology from Harvard University.

Jeremy Chan and Annabelle Allen also joined the company as Market Research Associates. Jeremy is finalising his PhD and Annabelle has recently completed a Masters in International Public Health.

“I think our extensive experience across the value chain, combined with our knowledge of the commercial environment, gives us a unique understanding of the many issues you can face developing or bringing products to market,” says Ms Herz.

She says the company’s recent growth and expansion has added and broadened its expertise and knowledge of the development process and commercial environment.

“Understanding the day-to-day realities is key to being able to assess a market opportunity, address development and commercial challenges, or recommend the best organisational structure to deliver an outcome.

“We have access to even greater expertise via the recent appointments and an extensive international network of scientific, medical and industry experts to ensure our advice is based on real insights,” she adds.

With his focus on Business Development, Mr Herz says the personal and tailored Biointelect approach is attractive to clients.

“Clients know the level of thinking we provide,” he says. “It’s about how we work closely with our clients to develop a tailored approach to an issue or challenge. Our strategic approach to problem solving, which is based on real knowledge and experience of developing, launching and optimising new products, can be applied to start-ups, companies or not-for-profits, in Australia, overseas or across regions.”

More information on Biointelect, its services, recent appointments and case studies, is available at the company’s website.